题目：Influenza, innate immunity, and future therapeutic strategies

报告人：Alan Chen-Yu Hsu 澳大利亚纽卡斯尔大学

时间：2018年9月26日（周三）13:30

地点：新民校区第二教学楼2103室

主办单位：白求恩医学部

报告人简介：

2010年博士毕业于澳大利亚纽卡斯尔大学，2011-2016年在澳大利亚纽卡斯尔大学从事博士后研究工作，2016年至今在澳大利亚纽卡斯尔大学呼吸研究中心担任研究员。2012年获得“Ann Woolcock Young Investigator Award”，2013年获得重点研究中心早期职业发展奖学金，2016年获得TSANZ/AstraZeneca 奖学金。20余篇相关研究成果发表SCI杂志上。

报告摘要：

Influenza is a contagion that has plagued mankind for many decades, and continues to pose concerns every year, with millions of infections globally. The frequent mutations and recombination of the influenza A virus cast a looming threat that antigenically novel strains/subtypes will rise with unpredictable pathogenicity and fear of it evolving into a pandemic strain.

The mechanisms of influenza virus infection, host immune responses, and how viruses evade from such defensive responses at the molecular and structural levels have been greatly investigated in the last 30 years. While this has advanced our understanding of virus-host interactions and human immunology, and has led to the development of several antiviral drugs, they have minimal impact on the clinical outcomes of infection. The heavy use of these drugs has also imposed selective pressure on IAV to evolve and develop resistance. Vaccination remains the cornerstone of public health efforts to protect against influenza, however rapid mass-production of sufficient vaccines is unlikely to occur immediately after the beginning of a pandemic. This therefore requires novel therapeutic strategies against this continually emerging infectious virus, with higher specificity and cross-reactivity against multiple strains/subtypes of IAVs.

  Here, current understandings of how host innate immune response controls viral replication and cause disease pathology will be discussed. The precise mechanisms of virus-host interaction can be utilized to develop novel, highly specific immuno-therapeutics that are effective and cross-protective against multiple strains/subtypes of IAV, in preparation for the advent of future IAVs and pandemics.